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Abstract
The objectives of this analysis were to assess the prevalence of Sjögren’s syndrome (SS) associated with rheumatoid arthritis
(RA) and to compare baseline characteristics of patients with RA with and without SS. Adult patients with RA from a large
observational US registry (Corrona RA), with ≥ 1 visit for assessment of SS status between 22 April 2010 and 28 February 2018,
were considered. Patients with RAwith versus without SS were compared. SS status was determined from a yes/no variable and
reported at enrollment into the Corrona RA registry and follow-up visits. Outcomes were unadjusted prevalence of SS in patients
with RA, prevalence of SS by RA disease duration, and baseline characteristics in patients with RA by SS status. Of 24,528
eligible patients, 7870 (32.1%) had a diagnosis of RA and SS. The unadjusted overall rate for SS prevalence in patients with RA
was 0.30 (95% confidence interval 0.29, 0.31). SS prevalence increased with increasing RA duration. Patients with RA with
versus without SS were more likely to be older, female, and seropositive; had a longer RA duration; higher disease activity; and a
higher incidence of comorbidities (hypertension, cardiovascular disease, malignancies, and serious infections), erosive disease,
and subcutaneous nodules at index date. Patients with RA and SS had a higher disease burden than those with RA only. The
prevalence of SS increased as duration of RA increased. RAwith SS was associated with seropositivity, more severe RA, extra-
articular manifestations, and comorbidities.
Key Points
• The overall prevalence of SS among patients with RA was 30%.
• The prevalence of SS increased with increasing RA disease duration.
• Identifying specific clinical characteristics of patients with RAwith SS, such as a greater incidence of extra-articular manifestations and comorbidities,
may help clinicians to better characterize this patient population.
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Introduction
Sjögren’s syndrome (SS) is a systemic autoimmune disease
with a wide variety of presentations which can be character-
ized as either glandular (e.g., dry eyes and/or mouth) or
extraglandular (e.g., musculoskeletal, cutaneous, neurologic,
pulmonary, or renal) manifestations [1, 2]. SS frequently oc-
curs with another autoimmune disease such as rheumatoid
arthritis (RA) [2, 3]; however, the prevalence and characteri-
zation of SS associated with RA are poorly understood [2,
4–6]. SS is commonly classified as “primary” or “secondary,”
depending on whether or not a coexisting autoimmune condi-
tion is present. Recent publications, however, favor more de-
scriptive terms, such as “SS alone” or “SS associated with
systemic or organ-specific autoimmune diseases.” This trend
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has been developed to more accurately describe secondary SS
in terms of which autoimmune disease is associated with SS
and because the autoimmune conditions are coexisting rather
than one being secondary to another [3].
A meta-analysis of 18 studies investigating SS associated
with RA found a global prevalence of 19.5% [7]. Prevalence
data for SS associated with RA in the USA are limited; one
registry reported a rate of 10.3% [8]. Rate estimates from
several European studies range from 7 to 31% [9–11]. The
presence of SS adds to the RA disease burden, negatively
impacts patients’ daily lives, and is associated with increased
comorbidities, pain, fatigue, and joint damage, and a higher
mortality rate [8, 12, 13].
SS may be a marker of more aggressive joint disease in
patients with RA [8]; thus, identifying specific characteristics
for patients with RA with SS may help clinicians to better
characterize this population. The aims of this analysis were
to assess the prevalence of SS associated with RA and to
compare baseline characteristics of patients with RA with
and without SS in the USA.
Materials and methods
Data source
The Corrona RA registry is an independent, prospective, na-
tional, observational cohort. Patients are recruited from 182
private and academic practice sites across 42 US states, with
781 participating rheumatologists. As of June 2019, the
Corrona RA registry included information on 52,757 patients.
Data on 397,236 patient visits and approximately 188,161
patient-years of follow-up time have been collected, with a
mean (standard deviation [SD]) patient follow-up of 4.5
(3.8; median, 3.3) years.
Study population
Patients aged ≥ 18 years with rheumatologist-diagnosed RA
enrolled in the Corrona RA registry between 22 April 2010
and 28 February 2018 were included. SS status was deter-
mined from a yes/no variable based on physician diagnosis,
reported into the Corrona RA registry at enrollment/follow-
ups. For SS patients, the index date was defined as the date the
provider first reported SS status as yes, and for patients with-
out SS, it was the date on which the provider first reported SS
status as no. Patients were included if they had ≥ 1 visit
assessing the SS status (yes/no) and ≥ 12 months of follow-
up after the index date to allow time for SS diagnosis. Patients
with missing SS information were excluded. The presence of
SS was determined by the clinical signs and symptoms of dry
eyes, and/or dry mouth, unrelated to medications. Physician
forms included a yes/no question regarding secondary SS
status. Baseline was defined as the index visit in which a
patient first reported a diagnosis of SS and RA or RA alone.
Study outcomes
The primary outcome was the unadjusted prevalence of
physician-reported SS associated with RA. Secondary out-
comes included unadjusted prevalence of SS by RA disease
duration and assessment of patients’ baseline characteristics
by SS status.
Statistical analysis
Unadjusted prevalence rate for SS associated with RA was
calculated, using the proportion exact confidence intervals
by Stata Software (version 15.1), excluding patients without
12-month follow-up after first SS report. For both prevalence
of SS associated with RA and SS by RA disease duration, the
95% confidence intervals (CI) for the proportion of patients
with SS alone and SS associated with RA were calculated
based on a normal distribution. Baseline characteristics were
summarized using descriptive statistics; frequency and per-
centage were calculated for categorical variables and means
(SD) were calculated for continuous variables. Health status
was measured by the five domains of the EuroQoL 5-
dimension questionnaire: mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression [14]. All analyses
were performed using Stata Release 15 (StataCorp LLC,
College Station, TX, USA).
Results
Patient disposition
Data were available for 35,156 patients with RA who had a
known SS status, of whom 24,528 patients had at least
12 months of follow-up (Fig. 1). Approximately one-third of
patients had RAwith SS (n = 7870; 32.1%).
Prevalence of SS in patients with RA
The unadjusted rate (excluding patients with < 12 months of
follow-up) for the prevalence of SS in patients with RA was
30.0% (95% CI 29.4%, 30.6%). The unadjusted SS rate in-
creased with RA disease duration from 14.4% in patients with
disease duration of 0 to 1 years to 38.8% in patients with
disease duration of > 10 years (Fig. 2).
Clinical characteristics
Compared with patients with RA only, patients with RAwith
SS were more likely to be female, older and have longer RA
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disease duration (Table 1). There were fewer patients with RA
with SS in full-time employment and more disabled or retired
patients compared with patients with RA only. Patients with
RA with SS had more baseline comorbidities (hypertension,
cardiovascular disease, and malignancies), erosive disease,
and subcutaneous nodules than patients with RA only.
Patients with RAwith SS experienced twice the incidence of
serious infections requiring hospitalization or intravenous
treatment than patients with RA only. Patients with RA with
SS, versus RA only, were more likely to be seropositive (anti-
cyclic citrullinated peptide-positive, rheumatoid factor-posi-
tive, and double-positive) and have a higher mean clinical
disease activity index score (Table 1). Patients with RA with
SS were more likely to be taking abatacept or other non-tumor
necrosis factor inhibitor biologic/targeted synthetic (ts)
disease-modifying antirheumatic drugs (DMARDs) than pa-
tients with RA only. Additionally, they were more likely to
have previously used > 1 conventional synthetic DMARD and
biologic/tsDMARD (Table 1). Compared with patients with
RA only, patients with RAwith SS were more likely to have
experienced morning stiffness and have higher meanmodified
health assessment questionnaire [15], patient pain, and Patient
Global Assessment scores. Patients with RA with SS were
more likely to report difficulties with walking, self-care, usual
RA diagnosed by a rheumatologist
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Corrona RA registry
22 April 2010 – 28 February 2018
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Without SS
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Fig. 1 Patient disposition.
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activities, pain and discomfort, and anxiety and depression
than patients with RA only (Fig. 3).
Discussion
In the large US-based Corrona RA registry, the preva-
lence of RA with SS was 30%, which is higher than that
previously reported in the US (10.3%) [8] and toward the
higher end of the range reported for Europe (7 to 31%)
[9–11]. The variance in the rates may be due to many
reasons, including sample size, the SS classification
criteria used, study population differences, and
patient—versus physician—reported diagnoses.
Conflicting results have been published regarding whether
RA disease duration affects the prevalence of SS, although
several studies had low patient numbers [4, 9, 11, 16–18].
An analysis of the Oslo Rheumatoid Arthritis Registry
(ORAR; n = 631) found no correlation between SS symptoms
and RA disease duration [11]; whereas a cross-sectional study
in an Indian hospital (N = 199) showed that patients with sec-
ondary SS had a longer disease duration than those without
secondary SS [18]. In addition, a larger study in Spanish pa-
tients (n = 788) diagnosed by rheumatologists found that the
prevalence of SS increased with RA disease duration from an
incidence (95%CI) of 2.3 (1.4, 3.7) at 2 years to 9.1 (6.9, 11.8)
at 10 years [9]. This finding is supported by our study, which
to the best of our knowledge is the largest to date investigating
patients with RAwith SS (n = 7870), and showed that a higher
prevalence of RA with SS was observed as RA duration
increased.
The comparison of the baseline characteristics showed that
compared with patients with RA only, patients with RAwith
SS were older, more likely female, and had longer RA disease
duration. In addition, RA with SS was associated with sero-
positivity; more severe RA; more health-related difficulties
such as pain and anxiety; a lower level of employment; and
a greater incidence of other extra-articular manifestations and
comorbidities. There are limited data available in the literature
regarding the characteristics of patients with RA and SS [8];
however, the data reported here are supported by a smaller
cross-sectional study of 85 patients with RA which showed
that patients with RAwith SS were more likely to be female
and have longer disease duration and higher frequency of RF
and/or anti-citrullinated protein antibody (ACPA) positivity
[8]. Similarly, a single-center study (n = 74) found that higher
disease scores and frequencies of RF positivity were reported
in patients with RAwith SS compared with those with either
RA or SS alone [4].
In contrast, a small cross-sectional study found no differ-
ences between patients with RA with SS (n = 11) and those
with RA alone (n = 296) regarding age, sex, RA disease dura-
tion, disease activity score, and ACPA seropositivity;
Table 1 Patient demographic and clinical characteristics at index date
Patients with RA
with SS
(n = 7870)
Patients with RA
only
(n = 16,658)
Age, years, mean (SD) 62.5 (11.9) 59.2 (13.1)
Sex, female 6617 (84.4) 12,229 (73.8)
Duration of RA, years, mean
(SD)
13.6 (11.0) 9.5 (9.2)
Work status n = 7692 n = 16,373
Full-time 2142 (27.8) 6530 (39.9)
Part-time 607 (7.9) 1389 (8.5)
Disabled 1237 (16.1) 1716 (10.5)
Retired 2986 (38.8) 5169 (31.6)
Other 720 (9.4) 1569 (9.6)
Comorbidities
Hypertension 2909 (37.0) 5214 (31.3)
CV disease* 1219 (15.5) 1710 (10.3)
Malignancy† 1223 (15.5) 1821 (10.9)
Serious infections‡ 795 (10.1) 845 (5.1)
Diabetes 775 (9.8) 1416 (8.5)
Asthma 403 (5.1) 590 (3.5)
COPD 270 (3.4) 355 (2.1)
ILD/pulmonary fibrosis 81 (1.0) 81 (0.5)
Anti-CCP-positive, n/m (%) 1999/3420 (58.5) 4076/7451 (54.7)
RF+, n/m (%) 2983/4296 (69.4) 6338/9492 (66.8)
Erosive disease, n/m (%) 2480/6650 (37.3) 4230/12,406
(34.1)
Subcutaneous nodules, n/m (%) 2700/7869 (34.3) 2886/16,640
(17.3)
CDAI, mean (SD) 13.4 (12.8) 11.3 (11.9)
Current medication use
TNFi biologic 2924 (37.2) 6390 (38.4)
Abatacept 591 (7.5) 980 (5.9)
Other non-TNFi
biologic/tsDMARD
781 (9.9) 962 (5.8)
csDMARD 7227 (91.8) 15,650 (93.9)
Number of prior biologics/tsDMARDs
0 2583 (32.8) 7593 (45.6)
1 2656 (33.7) 5592 (33.6)
≥ 2 2631 (33.4) 3473 (20.8)
Number of prior csDMARDs
0 367 (4.7) 1704 (10.2)
1 2984 (37.9) 8016 (48.1)
≥ 2 4519 (57.4) 6938 (41.6)
Patient-reported outcomes
mHAQ score, mean (SD); n 0.4 (0.5); 7659 0.3 (0.4); 16,466
Pain score, mean (SD); n 37.2 (28.7); 7829 31.2 (27.5); 16,549
Global assessment score, mean
(SD); n
35.3 (27.3); 7830 28.9 (26.4); 16,549
Morning stiffness, n/m (%) 5884/7717 (76.2) 11,628/16,334
(71.2)
Data are n (%) unless otherwise stated
Anti-CCP, anti-cyclic citrullinated peptide; CDAI, Clinical Disease Activity
Index; COPD, chronic obstructive pulmonary disease; csDMARD, conven-
tional synthetic disease-modifying antirheumatic drug; CV, cardiovascular;
ILD, interstitial lung disease; mHAQ, modified health assessment question-
naire; n/m, number of patients by total number of patients in the analysis; RA,
rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SS,
Sjögren’s syndrome; TNFi, tumor necrosis factor inhibitor; tsDMARD,
targeted synthetic disease-modifying antirheumatic drug
*History of coronary artery disease, myocardial infarction, congestive
heart failure requiring hospitalization, acute coronary syndrome, unstable
angina, cardiac revascularization procedure, cardiac arrest, ventricular
arrhythmia, stroke, transient ischemic attack, or other CV events
†History of lung cancer, breast cancer, lymphoma, skin cancer (melano-
ma and squamous), or other cancer
‡ Infection required hospitalization or IV treatment
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however, it showed that patients with RA and secondary SS
had a tendency for higher numbers of tender and swollen
joints and pain [17]. Data from a Finnish Registry showed that
patients with secondary SS (n = 709) were more likely to have
hematologic malignancies than those with RA alone (n =
9469; standard incidence ratio, 3.1% vs 1.7%) [19]. The dif-
ferences between groups in these descriptive studies may be a
result of the low number of patients with RA with SS in the
former study. The low patient numbers make comparisons
between studies difficult as differences may be due to SS,
factors associated with SS, or the randomness of the data.
A strength of our study is the source of our patient
data. Corrona is the largest US disease-registry that col-
lects data directly from both providers and patients at
the time of a routine clinical encounter, which allowed
for a very large number of patients with RA and SS to
be investigated. One potential limitation in every
registry-based analysis is whether findings are represen-
tative of, and generalizable to, the broader population.
Corrona does include rheumatology practices participat-
ing throughout the country in rural and urban areas in
academic and private settings and with access to broad
geographic locations and patients with diverse
sociodemographic origins. In addition, prior work com-
pared Medicare patients enrolled in Corrona with those
who are not part of the registry and found similar de-
mographic and comorbidity characteristics, supporting
the generalizability of the Corrona registry [20]. As
our study used a physician-reported diagnosis of SS
associated with RA, it is possible that providers may
differ in the criteria used to diagnose patients.
Differences in diagnosis criteria are shown throughout
the literature, suggesting a need for standardized diag-
nosis criteria for patients with SS and RA which are
easy to implement in everyday practice. In addition,
patients in the RA alone group required a questionnaire
entry for SS (yes/no), potentially leading to under
ascertainment.
Conclusions
In this large, US patient population, patients with RAwith SS
had a higher disease burden than those with RA alone; a
higher prevalence of SS was observed as RA disease duration
increased. Identifying specific characteristics of patients with
RAwith SS may help clinicians to better understand this pa-
tient population and the extra-articular manifestations of RA.
Additional studies are warranted to further understand the full
burden of SS in patients with RA and its impact on clinical and
patient-reported outcomes.
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